Literature DB >> 18522705

Transfusion-related immunomodulation by platelets is dependent on their expression of MHC Class I molecules and is independent of white cells.

Rukhsana Aslam1, Edwin R Speck, Michael Kim, John Freedman, John W Semple.   

Abstract

BACKGROUND: Transfusion-related immunomodulation (TRIM) has been correlated with the presence of white cells (WBCs) in blood transfusions, but the role of components such as platelets (PLTs) in mediating TRIM has not been extensively examined. We designed a murine PLT transfusion model to study whether leukoreduced PLTs mediate TRIM effects. STUDY DESIGN AND METHODS: CBA recipient mice were administered four weekly transfusions of either fresh (4 hr) or aged (24 and 72 hr) donor leukoreduced PLTs from allogeneic BALB/c mice and then transplanted with skin grafts from donor-matched mice. TRIM was measured by comparing the times to graft rejection and these were correlated with immunoglobulin G (IgG) antibody development measured by flow cytometry.
RESULTS: Compared with nontransfused control recipients, four transfusions of fresh, extremely leukoreduced (<0.05 WBCs/mL), allogeneic PLTs significantly (p < 0.002) reduced the recipient's ability to reject donor-matched skin grafts (survival >49 days compared with <14 days in nontransfused controls) despite the presence of high-titered serum IgG donor antibodies. In contrast, however, aged PLTs or fresh PLTs devoid of MHC Class I molecules were unable to affect skin graft survival nor stimulate antibody production. The PLT age-related inability to induce TRIM was shown to be due to loss of PLT-associated MHC Class I molecules; soluble supernatant MHC molecules that were transfused were unable to induce TRIM.
CONCLUSION: These results suggest that fresh PLTs can induce TRIM independently of WBCs due to their MHC antigen expression whereas aging results in loss of MHC and ability to mediate TRIM. The findings support the concept that either active MHC removal from fresh PLTs or passive removal by, for example, storage, may reduce any deleterious effects of TRIM in transfusion recipients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18522705     DOI: 10.1111/j.1537-2995.2008.01791.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  20 in total

1.  New frontiers in transfusion biology: identification and significance of mediators of morbidity and mortality in stored red blood cells.

Authors:  Katie Grimshaw; Julie Sahler; Sherry L Spinelli; Richard P Phipps; Neil Blumberg
Journal:  Transfusion       Date:  2011-04       Impact factor: 3.157

2.  Moving CLABSI prevention beyond the intensive care unit: risk factors in pediatric oncology patients.

Authors:  Matthew Kelly; Margaret Conway; Kathleen Wirth; Gail Potter-Bynoe; Amy L Billett; Thomas J Sandora
Journal:  Infect Control Hosp Epidemiol       Date:  2011-09-20       Impact factor: 3.254

Review 3.  Platelets and the immune continuum.

Authors:  John W Semple; Joseph E Italiano; John Freedman
Journal:  Nat Rev Immunol       Date:  2011-04       Impact factor: 53.106

4.  Pathogen-reduced PRP blocks T-cell activation, induces Treg cells, and promotes TGF-β expression by cDCs and monocytes in mice.

Authors:  Johnson Q Tran; Marcus O Muench; Rachael P Jackman
Journal:  Blood Adv       Date:  2020-11-10

5.  Global proteome analysis identifies active immunoproteasome subunits in human platelets.

Authors:  Cordula Klockenbusch; Geraldine M Walsh; Lyda M Brown; Michael D Hoffman; Vladimir Ignatchenko; Thomas Kislinger; Juergen Kast
Journal:  Mol Cell Proteomics       Date:  2014-08-21       Impact factor: 5.911

Review 6.  Platelets in Pulmonary Immune Responses and Inflammatory Lung Diseases.

Authors:  Elizabeth A Middleton; Andrew S Weyrich; Guy A Zimmerman
Journal:  Physiol Rev       Date:  2016-08-03       Impact factor: 37.312

7.  Platelets as immune-sensing cells.

Authors:  Rick Kapur; John W Semple
Journal:  Blood Adv       Date:  2016-11-22

8.  Mature murine megakaryocytes present antigen-MHC class I molecules to T cells and transfer them to platelets.

Authors:  Anne Zufferey; Edwin R Speck; Kellie R Machlus; Rukhsana Aslam; Li Guo; Mark J McVey; Michael Kim; Rick Kapur; Eric Boilard; Joseph E Italiano; John W Semple
Journal:  Blood Adv       Date:  2017-09-08

9.  2016 proceedings of the National Heart, Lung, and Blood Institute's scientific priorities in pediatric transfusion medicine.

Authors:  Pablo Cure; Melania Bembea; Stella Chou; Allan Doctor; Anne Eder; Jeanne Hendrickson; Cassandra D Josephson; Alan E Mast; William Savage; Martha Sola-Visner; Philip Spinella; Simon Stanworth; Marie Steiner; Traci Mondoro; Shimian Zou; Catherine Levy; Myron Waclawiw; Nahed El Kassar; Simone Glynn; Naomi L C Luban
Journal:  Transfusion       Date:  2017-03-28       Impact factor: 3.157

10.  History of blood transfusion before 1990 is associated with increased risk for cancer mortality independently of liver disease: a prospective long-term follow-up study.

Authors:  Yusuke Inoue; Yasuhiko Wada; Yutaka Motohashi; Akio Koizumi
Journal:  Environ Health Prev Med       Date:  2009-12-17       Impact factor: 3.674

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.